BCL2L11 and cancer: Compared with healthy volunteers, patients in the consecutive cancer cohort (19% vs. 14%, P = 0.018) had significantly higher frequencies of BIM deletion polymorphism and patients in the metastatic cancer cohort (19% vs. 14%, P = 0.089) had a trend toward higher frequencies of BIM deletion polymorphism (Table 1).